Replimune Group, Inc. filed its Form 10-Q with the SEC on October 28, 2026, covering the quarterly and six-month periods ended September 30, 2026, and reporting a net loss of $126.887 million for the first half of its fiscal year.

Key Highlights

  • Net loss for the six months ended September 30, 2026: $126.887 million, compared with $169.793 million in the same period a year earlier, according to the filing.
  • Net loss for the three months ended September 30, 2026: $57.121 million, or $0.54 per basic and diluted share, versus $83.100 million, or $0.90 per share, in the prior-year quarter.
  • Cash and cash equivalents at September 30, 2026: $307.833 million, up from $209.024 million at March 31, 2026.
  • Shares issued and outstanding at September 30, 2026: 94,805,154, compared with 82,716,923 at March 31, 2026, reflecting an issuance of 9,701,490 shares of common stock and prefunded warrants during the quarter.
  • Total stockholders' equity at September 30, 2026: $204.778 million, up from $166.160 million at March 31, 2026.
  • Total operating expenses for the six months: $124.529 million, consisting of $83.644 million in research and development and $40.885 million in selling, general and administrative expenses.

Replimune's Second-Quarter and Half-Year Financial Results Through September 30, 2026

According to the Form 10-Q filed with the SEC for the period ended September 30, 2026 (NASDAQ:REPL), Replimune Group reported a net loss of $57.121 million for the three months ended September 30, 2026, compared with a net loss of $83.100 million for the same quarter in the prior fiscal year. For the six-month period, the company disclosed a net loss of $126.887 million versus $169.793 million in the comparable prior-year period. Loss per common share, basic and diluted, was $0.54 for the quarter and $1.26 for the half-year, the filing stated.

Total operating expenses for the three months ended September 30, 2026, were $56.281 million, comprised of $34.365 million in research and development costs and $21.916 million in selling, general and administrative costs, according to the filing. For the six months, research and development expenses were $83.644 million and selling, general and administrative expenses were $40.885 million. The filing reported total other expense, net, of $840 thousand for the quarter, driven in part by $2.523 million in interest expense on debt obligations and partially offset by $1.880 million in investment income.

On the balance sheet, the company reported cash and cash equivalents of $307.833 million at September 30, 2026, compared with $209.024 million at the prior fiscal year-end of March 31, 2026. Short-term investments, which stood at $59.865 million at March 31, 2026, were zero at September 30, 2026, according to the filing. The company also disclosed a new inventory line item of $9.867 million at September 30, 2026, which was not present at March 31, 2026. Long-term debt, net of discount, increased to $99.766 million from $83.308 million over the same period. During the quarter ended September 30, 2026, the filing disclosed an issuance of common stock generating net proceeds contributing to additional paid-in capital of $109.970 million, as well as issuance of prefunded warrants adding $31.020 million to additional paid-in capital. The accumulated deficit stood at $1.389406 billion as of September 30, 2026.

What Was Disclosed

Replimune Group filed a quarterly report covering the three and six months ended September 30, 2026, disclosing net losses, operating expenses, balance sheet changes including new inventory, increased cash, higher long-term debt, and equity raises through common stock and prefunded warrant issuances.